This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Insulin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Insulin is produced by the beta cells of the islets of Langerhans in the pancreas. It consists of an A-chain of 21 amino acids and a B-chain of 30 aminoacids. Pro-insulin, the precursor of insulin, is a single polypeptide chain 1.5 times the size of insulin. It is cleaved into insulin and C-peptide which are therefore secreted in equimolar amounts. C-peptide levels reflect endogenous insulin secretion and are widely used for research purposes. About 3-5% of pro-insulin escapes the cleavage process and is secreted intact.

There are various types of insulin preparation used in the treatment of diabetes mellitus:

  • very rapidly-acting insulin e.g. insulin lispro or insulin aspart
  • short-acting e.g. human actrapid
  • intermediate-acting insulin e.g. human insulatard
  • long-acting-acting insulin
  • mixtures containing specific proportions of short and intermediate-acting insulins

Commercial insulin is generally recombinant human insulin; although animal insulins are still available.

All commercial insulins come in a strength of 100 units/ml.

Notes:

  • long-acting human insulin analogue are an alternative to intermediate-acting insulin

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.